Goldman Sachs
BFRI icon

Goldman Sachs’s Biofrontera BFRI Stock Holding History

Goldman Sachs’s Portfolio BFRI Stock Details BFRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-45,558
Closed -$49.7K – 6060
2024
Q4 		$49.7K Buy
+45,558
New +$43.1K ﹤0.01% 5844

Other funds holding BFRI

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs's BFRI Position: Q1 2025 in Review

Goldman Sachs sold out of Biofrontera (BFRI) in Q1 2025, closing a stake of 45,558 shares — an estimated $49.7K sold.

Goldman Sachs first reported a position in BFRI in Q4 2024 and held it in 1 quarter. The position peaked at $49.7K in Q4 2024. 12 funds tracked by Wall St. Rank hold BFRI as of Q1 2025.

  • Goldman Sachs reported no remaining Biofrontera position as of Q1 2025 after selling out during the quarter.
  • Goldman Sachs sold 45,558 Biofrontera shares in Q1 2025, an estimated $49.7K.
  • Goldman Sachs first reported a position in Biofrontera in Q4 2024 and held it in 1 quarter.
  • Goldman Sachs's Biofrontera position peaked at $49.7K in Q4 2024.
  • 12 funds tracked by Wall St. Rank held Biofrontera as of Q1 2025.

Based on Goldman Sachs's 13F filing for Q1 2025, filed 9 May 2025.